About KalVista


KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet need.

We have developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

The strategy is to develop a portfolio of oral molecules and evaluate multiple candidates in the clinic to provide one or more potential best-in-class therapies for HAE and DME patients. 



We are developing KVD900 as an on-demand therapy for acute HAE attacks and reported positive results in a Phase 2 trial. KVD824 is in development for prophylactic treatment of HAE. Our oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor called KVD001, completed a Phase 2 clinical trial.

We have an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with the capability to bring small molecules through the clinic to commercialization.

Our offices and labs are in Cambridge, MA and Salisbury, UK.